APP

Diseases

• Alzheimer disease1 trial
• Coronary artery disease1 trial

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

• Publication

  Overexpression of hippocampal AdipoR1 ameliorates cognitive dysfunction in APP/PS1 mice through inhibiting NLRP3-Mediated neuronal pyroptosis.

  26 Oct 2026· Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics· PUBMED

• Publication

  Comment on "High-intensity interval training modulates APP expression and reduces neuronal apoptosis in a β-amyloid-induced model of Alzheimer's disease: hippocampal evidence".

  20 Oct 2026· Experimental brain research· PUBMED

• Publication

  [Suanzaoren Decoction inhibits neuroinflammation and alleviates hippocampal neuronal injury in APP/PS1 transgenic mice by regulating the Hippo-YAP pathway].

  20 Oct 2026· Nan fang yi ke da xue xue bao = Journal of Southern Medical University· PUBMED

• Publication

  miR‑660‑5p ameliorates neuronal damage in Alzheimer's disease via targeting APP.

  17 Oct 2026· Neurogenetics· PUBMED

• Publication

  CXCL16-driven neutrophil extracellular traps promote osteoporosis in APP/PS1 mice by disrupting bone remodeling.

  8 Oct 2026· Bone· PUBMED

• Publication

  Intranasal Artesunate Ameliorates Hippocampal LFP Abnormalities and Cellular Apoptosis in APP/PS1 Mice via a Mechanism Involving GHRH/PI3K/AKT Signaling.

  6 Oct 2026· Molecular neurobiology· PUBMED

• Publication

  Correction: Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer's disease.

  2 Oct 2026· Alzheimer's research & therapy· PUBMED

• Publication

  The influence of mutant genes APP and PSEN1 on hippocampal asymmetry in 5xFAD mice, transgenic model of Alzheimer disease.

  1 Oct 2026· Vavilovskii zhurnal genetiki i selektsii· PUBMED

• Publication

  High-intensity interval training modulates APP expression and reduces neuronal apoptosis in a β-amyloid-induced model of Alzheimer's disease: hippocampal evidence.

  25 Sept 2026· Experimental brain research· PUBMED

• Publication

  Humanized APP is the primary determinant of regional brain volume in humanized APOE knock-in mice: a cross-sectional ex vivo MRI study.

  24 Sept 2026· Alzheimer's & dementia (New York, N. Y.)· PUBMED

• Publication

  Shenghui Decoction ameliorates cognitive impairment and neuroinflammation in APP/PS1 mice via modulation of the HMGB1/TLR4/NLRP3 pathway.

  24 Sept 2026· Journal of ethnopharmacology· PUBMED

• Publication

  Integrated multi-omics identifies lineage-dependent myeloid cells recruitment and the APP-CD74 axis as an immunoregulatory target in pediatric high-grade glioma.

  22 Sept 2026· Acta neuropathologica· PUBMED

• Publication

  Tinosinenside A ameliorates Alzheimer's disease-related pathology in APP/PS1 mice, accompanied by reduced neuroinflammation and altered microglial phenotype-associated marker expression.

  22 Sept 2026· Naunyn-Schmiedeberg's archives of pharmacology· PUBMED

• Publication

  D-Cycloserine ameliorates innate fear deficits in young adult male APP/PS1 mice: Involvement of GluN2B-containing NMDA receptor.

  19 Sept 2026· Pharmacology, biochemistry, and behavior· PUBMED

• Publication

  A coordinated multi-target approach based on chondroitin sulphate nano-selenium mitigates Alzheimer's disease pathologies in APP/PS1 mice.

  15 Sept 2026· Frontiers in pharmacology· PUBMED

• Publication

  Nrf2 overexpression ameliorates cognitive deficits and neuronal damage in APP/PS1 mice via attenuation of Aβ deposition and neuronal ferroptosis.

  13 Sept 2026· Neuroscience letters· PUBMED

• Publication

  Correlations of PSEN1, PSEN2, and APP missense variants on the production of Aβ peptides against variant effect prediction.

  7 Sept 2026· Alzheimer's & dementia (New York, N. Y.)· PUBMED

• Preprint

  Histone Deacetylase Inhibitors Improve Memory Function and Decrease Neuropathology in APP/PS1 Mice.

  26 Aug 2026· Research square· PUBMED

• Publication

  LAMTOR1 sorts APP to late endosomes via AP-3-mediated trafficking.

  26 Aug 2026· Journal of molecular cell biology· PUBMED

• Preprint

  Hepatic and Brain Spatial Gene Expression Changes in Intragastric Alcohol Fed APP/PS1 Alzheimer's Disease Mouse Model.

  24 Aug 2026· Research square· PUBMED

• Publication

  Liuwei Dihuang pills attenuates cognitive dysfunction in APP/PS1 mice through restoring mitochondrial homeostasis and activating the IRS/AKT/GSK3β insulin signaling pathway.

  20 Aug 2026· Frontiers in pharmacology· PUBMED

• Publication

  Isoserine Improves Spatial Memory and Remodels Synaptic and Inflammatory Gene-Expression Programs in APP/PS1 Mice.

  18 Aug 2026· Cells· PUBMED

• Publication

  Oral administration of melatonin modulates macrophage polarization via modulating the Vegf signaling pathway and ameliorates Alzheimer's disease in APP/PS1 mice.

  17 Aug 2026· Brain research bulletin· PUBMED

• Publication

  TP53 status is associated with differential stress-marker expression and APP maturation in colon cancer cells.

  11 Aug 2026· Molecular biology reports· PUBMED

• Publication

  Adaptive-to-maladaptive IRE1α signaling as a driver of amyloidogenic APP processing in Alzheimer's disease.

  11 Aug 2026· Frontiers in molecular biosciences· PUBMED

• Preprint

  APP Dosage and Extracellular Domain Variants Drive Distinct Defects in Neurogenesis modeled in Down Syndrome iPS cells.

  6 Aug 2026· bioRxiv : the preprint server for biology· PUBMED

• Publication

  Distinct amyloid-β filament fold in individuals with APP Flemish mutation.

  6 Aug 2026· Nature structural & molecular biology· PUBMED

• Publication

  Alzheimer's disease-linked Flemish APP mutation defines a distinct amyloid-β fold.

  1 Aug 2026· Nature structural & molecular biology· PUBMED

• Publication

  APOE and genetic risk variants influence Alzheimer's disease onset in carriers of an extra copy of APP, with and without Down syndrome.

  1 Aug 2026· Alzheimer's & dementia : the journal of the Alzheimer's Association· PUBMED

• Publication

  EV-transferred miR-7111-3p inhibits malignant phenotypes and tumor growth in nasopharyngeal carcinoma via targeting APP-regulated epithelial-mesenchymal transition.

  30 Jul 2026· Journal of translational medicine· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.